Literature DB >> 24681080

Effects of topical steroids on tight junction proteins and spongiosis in esophageal epithelia of patients with eosinophilic esophagitis.

David A Katzka1, Ravikanth Tadi2, Thomas C Smyrk3, Eesha Katarya2, Anamay Sharma2, Deborah M Geno2, Michael Camilleri2, Prasad G Iyer2, Jeffrey A Alexander2, Navtej S Buttar2.   

Abstract

BACKGROUND & AIMS: The allergic response associated with eosinophilic esophagitis (EoE) occurs when food antigens permeate tight junction-mediated epithelial dilated intercellular spaces. We assessed whether levels of tight junction proteins correlate with the dilation of intercellular spaces (spongiosis) and the effects of topical steroids on these parameters.
METHODS: We assessed esophageal biopsy samples from 10 patients with active EoE treated with topical fluticasone, 10 untreated patients, and 10 patients without esophageal disease (controls) for degree of spongiosis. Immunohistochemical assays were used to determine the levels of the tight junction proteins filaggrin, zonula occludens (ZO)-1, ZO-2, ZO-3, and claudin-1. Histology and immunohistochemistry results were assessed blindly, with levels of tight junction proteins and degree of spongiosis rated on scales of 0 to 3.
RESULTS: The mean degrees of spongiosis in untreated and treated patients with EoE were 1.3 and 0.4, respectively (P = .016). Esophageal epithelia did not stain significantly for ZO-1 or ZO-2. Filaggrin was observed in a predominant cytoplasmic pattern, compared with the cytoplasmic and membranous patterns of ZO-3 and claudin-1. In biopsy specimens from patients with active EoE, the mean staining intensities for filaggrin, ZO-3, and claudin-1 were 1.6, 1.4, and 0.7, respectively. In biopsy specimens from patients treated with fluticasone, levels of filaggrin, ZO-3, and claudin-1 were 2.8 (P = .002 compared with untreated patients), 1.7 (P = .46 compared with untreated patients), and 1.3 (P = .25 compared with untreated patients), respectively. The correlation between the level of filaggrin and the degree of spongiosis was r = 0.23, and between ZO-3 staining and the degree of spongiosis was r = .016 (P = .001 for filaggrin vs ZO-3 staining).
CONCLUSIONS: Filaggrin, ZO-3, and claudin-1 (but not ZO-1 or ZO-2) are detected in the esophageal mucosa of patients with EoE treated with steroids and individuals without esophageal disease. Without treatment, spongiosis increases, corresponding with reduced levels of filaggrin, ZO-3, and claudin-1. Loss of tight junction regulators and dilation of intercellular spaces appear to be involved in the pathophysiology of EoE and could be targets for treatment.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allergy; Esophagus; Inflammation; Therapy

Mesh:

Substances:

Year:  2014        PMID: 24681080     DOI: 10.1016/j.cgh.2014.02.039

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  37 in total

Review 1.  Eosinophilic Esophagitis.

Authors:  Glenn T Furuta; David A Katzka
Journal:  N Engl J Med       Date:  2015-10-22       Impact factor: 91.245

Review 2.  Mucosal Impedance: a New Approach to Diagnosing Gastroesophageal Reflux Disease and Eosinophilic Esophagitis.

Authors:  Caroline Barrett; Yash Choksi; Michael F Vaezi
Journal:  Curr Gastroenterol Rep       Date:  2018-06-09

Review 3.  Emerging therapies for eosinophilic esophagitis.

Authors:  Thomas Greuter; Ikuo Hirano; Evan S Dellon
Journal:  J Allergy Clin Immunol       Date:  2019-11-06       Impact factor: 10.793

Review 4.  Recent advances in the pathological understanding of eosinophilic esophagitis.

Authors:  Antonella Cianferoni; Jonathan M Spergel; Amanda Muir
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-10-15       Impact factor: 3.869

5.  Development and Validation of a Mucosal Impedance Contour Analysis System to Distinguish Esophageal Disorders.

Authors:  Dhyanesh A Patel; Tina Higginbotham; James C Slaughter; Muhammad Aslam; Elif Yuksel; David Katzka; C Prakash Gyawali; Melina Mashi; John Pandolfino; Michael F Vaezi
Journal:  Gastroenterology       Date:  2019-01-31       Impact factor: 22.682

6.  Presence of intraepithelial food antigen in patients with active eosinophilic oesophagitis.

Authors:  E V Marietta; D M Geno; T C Smyrk; A Becker; J A Alexander; M Camilleri; J A Murray; D A Katzka
Journal:  Aliment Pharmacol Ther       Date:  2016-11-22       Impact factor: 8.171

7.  Influence of reflux and central obesity on intercellular space diameter of esophageal squamous epithelium.

Authors:  Christopher H Blevins; Anamay N Sharma; Michele L Johnson; Deborah Geno; Milli Gupta; Adil E Bharucha; David A Katzka; Prasad G Iyer
Journal:  United European Gastroenterol J       Date:  2015-07-24       Impact factor: 4.623

Review 8.  Recent discoveries and emerging therapeutics in eosinophilic esophagitis.

Authors:  Aakash Goyal; Edaire Cheng
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

9.  Eosinophilic Esophagitis: Leaky Gullet or Leaky Gut?

Authors:  David A Katzka
Journal:  Am J Gastroenterol       Date:  2017-07       Impact factor: 10.864

Review 10.  New Developments in the Diagnosis and Treatment of Eosinophilic Esophagitis.

Authors:  Quan M Nhu; Fouad J Moawad
Journal:  Curr Treat Options Gastroenterol       Date:  2019-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.